ArticleOncotarget2016
Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 41 citations in OpenAlex.
- Molecular determinants of AR-enhancer interaction and cistrome reprogramming in prostate cancer progression.Endocrine-related cancer · 2026Review
- Review
- Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.Oncology reports · 2024Article
- Identification of 6-methyladenosine sites using novel feature encoding methods and ensemble models.Scientific reports · 2024Article
- A lncRNA from the FTO locus acts as a suppressor of the mMolecular cell · 2023Article
- A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.Journal of experimental & clinical cancer research : CR · 2023Article
- Switching mechanism from AR to EGFR signaling via 3-O-sulfated heparan sulfate in castration-resistant prostate cancer.Scientific reports · 2023Article
- Article
- Construction and evaluation of a prognostic risk model of tumor metastasis-related genes in patients with non-small cell lung cancer.BMC medical genomics · 2022Article
- Enhancer RNA: What we know and what we can achieve.Cell proliferation · 2022Review
- Roles of enhancer RNAs in sex hormone-dependent cancers.Journal of cancer research and clinical oncology · 2022Review
- Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcomaFrontiers in genetics · 2022Article
- cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries.BMC bioinformatics · 2021Article
- Context-Dependent Roles of RNA Modifications in Stress Responses and Diseases.International journal of molecular sciences · 2021Review
- Enhancer RNA SLIT2 Inhibits Bone Metastasis of Breast Cancer Through Regulating P38 MAPK/c-Fos Signaling Pathway.Frontiers in oncology · 2021Article
- Functional roles of antisense enhancer RNA for promoting prostate cancer progression.Theranostics · 2021Article
- Downregulation of LUZP2 Is Correlated with Poor Prognosis of Low-Grade Glioma.BioMed research international · 2020Article
- Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity.Cellular and molecular life sciences : CMLS · 2018Review
- Genome-wide association study identifies two loci influencing plasma neurofilament light levels.BMC medical genomics · 2018Article
- Current Advances on the Important Roles of Enhancer RNAs in Gene Regulation and Cancer.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Enzalutamide is a second-generation anti-androgen for treatment of castration-resistant prostate cancer (CPRC). It prolongs survival of CRPC patients, but its overall survival benefit is relatively modest (4.8 months) and by 24 months most patients progress on enzalutamide. To date, however, the molecular mechanisms underlying enzalutamide resistance remain elusive. Herein, we report enzalutamide treatment-induced alterations of androgen receptor (AR)-regulated enhancer RNAs (AR-eRNAs) and their roles in enzalutamide-resistant growth and survival of CRPC cells. AR chromatin immunoprecipitation and high throughput sequencing (ChIP-seq) and RNA-seq analyses revealed that 188 and 227 AR-eRNAs were differentially expressed in enzalutamide-resistant LNCaP and C4-2 cells, respectively. The AR-eRNAs upregulated in C4-2 cells and downregulated in LNCaP cells were selected through meta-analysis. Expression of AR-eRNAs and related mRNAs in the loci of FTO, LUZP2, MARC1 and NCAM2 were further verified by real-time RT-PCR. Silencing of LUZP2 inhibited, but silencing of MARC1 increased the growth of enzalutamide-resistant C4-2 cells. Intriguingly, meta-analysis showed that expression of LUZP2 mRNA increased in primary tumors compared to normal prostate tissues, but decreased again in metastatic CRPC. Our findings suggest that eRNA alteration profiling is a viable new approach to identify functional gene loci that may not only contribute to enzalutamide-resistant growth of CRPC, but also serve as new targets for CRPC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.